Abstract
There is great interest in any new discoveries in malaria vaccine research. Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) shows promise in this area and may be used together with other merozoite antigens as a potential vaccine. In the present study, a bioinformatics prediction approach was applied to a PfRH5 B-cell epitope, and two B-cell epitope distributions were selected. Antibodies against the two PfRH5 distributions were obtained and the growth activity inhibition was measured. No inhibition of the P. falciparum CY strain was found, but the growth of the P. falciparum 3D7 strain was inhibited by all of the antibodies, in contrast to the results of other studies. It was additionally found that certain quantities of protein led to the inhibition of the parasitic invasion. Equally noteworthy was that the survival time of the group immunized with a portion of PfRH5 was significantly longer than that of the group immunized with the full-length protein, following infection by P. berghei ANKA. The present study produced conflicting results in in vitro and in vivo experiments, although the accuracy of the evaluation may be lessened due to the use of a murine malaria model. The findings of the present study may indicate that PfRH5 may not be suitable in malaria vaccine research.
Highlights
Malaria remains one of the most serious infectious diseases of the 21st century
RTS,S/AS01 is based on the major Plasmodium circumsporozoite surface protein and has reached phase III clinical trials; it is known that this vaccine does not confer complete sterile protection [1]
In order to determine the effect of the immune sera on merozoite invasion inhibition, schizonts from the P. falciparum 3D7 strain were purified and used in an Vaccination against malaria is generally presumed to be the most cost‐effective way of protecting against the disease, and it is hoped that it can potentially eradicate malaria from the world
Summary
Malaria remains one of the most serious infectious diseases of the 21st century. The development of an 80% efficacious malaria vaccine by 2025, which could offer protection for ≥4 years, is a worldwide goal. RTS,S/AS01 is raising the bar in the development and approval of a first‐generation malaria vaccine that has >50% protective efficacy against severe disease and mortality and lasts longer than one year. The parasite invasion process involves the duffy binding‐like protein family [2,3] and Plasmodium falciparum reticulocyte‐binding protein homologs (PfRHs) [4]. Among these proteins, PfRH5 is vital for erythrocyte invasion [5] and has become a promising vaccine target [6]. Due to the lack of a suitable animal model [9], the in vivo immune effects of partial and full‐length fragments of PfRH5 remain unknown. The present study established a rodent model to evaluate the effects of P. falciparum
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have